TL;DR
Ascletis has submitted two IND applications to the US FDA for potential obesity treatments. The filings include a monthly peptide injection and a combined formulation targeting multiple pathways. The move signals progress in the company’s development pipeline and could impact future obesity therapies.
Ascletis has submitted two Investigational New Drug (IND) applications to the US Food and Drug Administration (FDA) for novel obesity treatments, marking a significant step toward clinical trials. The filings include a once-monthly peptide injection, ASC36, which acts as a amylin receptor agonist, and a co-formulation, ASC36_35, combining ASC36 with a peptide GLP-1R/GIPR agonist, ASC35. This development underscores Ascletis’ efforts to expand its pipeline in the obesity treatment space and could influence future therapeutic options.
According to a press release from Ascletis, the company has formally submitted two IND applications to the FDA, aiming to initiate clinical trials for its experimental obesity drugs. The first, ASC36, is a once-monthly injectable peptide designed to target the amylin receptor, which plays a role in appetite regulation and energy balance. The second, ASC36_35, is a fixed-dose combination that pairs ASC36 with ASC35, a peptide agonist targeting both GLP-1 and GIP receptors, pathways known to influence weight loss and glucose metabolism.
Ascletis stated that the IND submissions are part of its strategic effort to develop innovative treatments for obesity, a condition affecting millions worldwide. The company did not specify the expected timeline for clinical trial initiation but emphasized its commitment to advancing these candidates through the regulatory process.
Potential Impact on Obesity Treatment Landscape
The submission of these IND applications marks a key milestone for Ascletis and could lead to new therapeutic options for obesity, a condition with limited effective long-term treatments. The development of a monthly injectable peptide and a co-formulated drug targeting multiple pathways reflects a broader trend toward multi-mechanism approaches. If successful, these drugs could offer improved efficacy and convenience over existing therapies, potentially influencing treatment guidelines and patient outcomes.
GLP-1 GIP receptor agonist injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Recent Advances and Market Need for Obesity Drugs
Obesity remains a global health challenge, with rising prevalence and associated risks such as diabetes and cardiovascular disease. Current pharmacological options include GLP-1 receptor agonists like semaglutide, which have shown significant weight loss benefits but often require daily injections. The development of monthly or combination therapies aims to improve adherence and effectiveness. Ascletis has been investing in peptide-based drugs targeting metabolic pathways, with prior research indicating promising results in preclinical studies. The recent IND filings suggest the company is progressing toward clinical validation of these candidates.
“The IND submissions represent a major step forward in our mission to develop innovative, effective treatments for obesity. We are committed to advancing these candidates through clinical trials and toward potential approval.”
— Ascletis spokesperson
monthly peptide obesity injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unclear Timeline and Clinical Trial Outcomes
It is not yet confirmed when clinical trials will commence, as the IND approval process involves review periods that vary. Additionally, the efficacy and safety of these candidates remain to be proven through subsequent trial phases. The success of the drugs in trials will determine their future regulatory approval and market potential.
amylin receptor agonist medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps in Regulatory and Clinical Development
Following the IND submissions, Ascletis will await FDA review and approval to begin clinical trials. The company is likely to initiate Phase 1 studies to assess safety and dosage, with subsequent phases evaluating efficacy. Monitoring trial progress and results will be critical to understanding the future of these treatments.
combination obesity treatment injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the main features of Ascletis’ obesity drugs?
The drugs include a monthly peptide injection targeting the amylin receptor and a co-formulation combining this with GLP-1 and GIP receptor agonists, aiming to improve efficacy and patient adherence.
Why is submitting IND applications important?
IND submissions are a critical step that allows the company to begin clinical trials in humans, which are necessary for regulatory approval and eventual market entry.
When might these drugs become available to patients?
It is too early to predict exact timelines. Approval depends on successful clinical trial outcomes and regulatory review, which can take several years.
How do these drugs differ from existing obesity treatments?
These candidates aim to offer monthly dosing and combine multiple mechanisms of action, potentially providing improved effectiveness and convenience over current daily injections.
What are the risks involved in clinical trials?
As with all experimental drugs, there are potential safety concerns and the possibility that the drugs may not demonstrate sufficient efficacy to proceed further.
Source: primary
